Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:08:49.394Z.
Calculation as of: 2026-10-06T18:08:49.394Z.
Quote observation: 2026-10-06T18:05:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869efbf6e11e98c8b36b953a9b631e7639c239a9e2012f11ad9cca4b0e6b7a7d
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $638.60M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $634.98M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $632.99M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $616.15M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $664.91M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 114.38 | 37.43 | 206.22 | 206.22 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $667.06M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $670.59M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.41
Forward EPS (Est.)
$-0.36
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
